|
|
 |
 Since 1998, Mr. Gifford has led The Foundry in all of its activities, including the invention, identification and early development of new technologies, the formation, financing, staffing and growth of new companies, and serving as a board member of the new ventures. Prior to The Foundry, Mr. Gifford was Vice President of Research and Development at Heartport, Inc.. From 1993-1998, he built and led a 62-person team developing a wide variety of novel devices and procedures for Minimally Invasive Cardiac Surgery that were instrumental in the company's enormously successful public offering in 1996.
In 1992, Mr. Gifford co-founded and served as managing director of Bavaria Medizin Technologie (BMT), GmbH, establishing a German source for innovation and production of catheters for Interventional Cardiology. In 1990, Mr. Gifford and John B. Simpson, MD, Ph.D., founded Cardiovascular Therapeutic Technologies, Inc., a business devoted to the development of innovative local drug delivery catheters. Eli Lilly and Company acquired this business in 1991. From 1985-1990, Mr. Gifford worked at Devices for Vascular Intervention (DVI), where he was the driving force behind the design of the company's first generation Peripheral and Coronary atherectomy systems. In addition, during this period he served in various Clinical Research and Marketing capacities. Before joining DVI, Hanson worked in an engineering role at Oximetrix, Inc.
Mr. Gifford is a co-inventor on over 80 issued U.S. patents and more than 100 pending US patent applications. He earned his B.S. degree in mechanical engineering from Cornell University. Mr. Gifford serves as Chairman of the Board of Directors for Ardian. He is a Director of Cabochon Aesthetics, Cierra, Concentric Medical, Emphasys Medical, Evalve and The Foundry. |
